Abingworth’s ChemoCentryx, Inc. CCXI Stock Holding History

Abingworth’s Portfolio CCXI Stock Details CCXI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-215,000	Closed	-$533K	–	21
2016 Q1	$533K	Hold	215,000	–	–	0.5%	16
2015 Q4	$1.74M	Hold	215,000	–	–	1.05%	16
2015 Q3	$1.3M	Hold	215,000	–	–	0.76%	15
2015 Q2	$1.77M	Buy	215,000 +105,300	+96%	+$837K	0.8%	13
2015 Q1	$824K	Buy	+109,700	New	+$857K	0.35%	15

Other funds holding CCXI

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Abingworth's CCXI Position: Q2 2016 in Review

Abingworth sold out of ChemoCentryx, Inc. (CCXI) in Q2 2016, closing a stake of 215,000 shares — an estimated $533K sold.

Abingworth first reported a position in CCXI in Q1 2015 and held it in 5 quarters. The position peaked at $1.77M in Q2 2015. 77 funds tracked by Wall St. Rank hold CCXI as of Q2 2016.

Abingworth reported no remaining ChemoCentryx, Inc. position as of Q2 2016 after selling out during the quarter.
Abingworth sold 215,000 ChemoCentryx, Inc. shares in Q2 2016, an estimated $533K.
Abingworth first reported a position in ChemoCentryx, Inc. in Q1 2015 and held it in 5 quarters.
Abingworth's ChemoCentryx, Inc. position peaked at $1.77M in Q2 2015.
77 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q2 2016.

Based on Abingworth's 13F filing for Q2 2016, filed 12 Aug 2016.